The ErbB2-antigen is targetable with vaccines that potentially trigger high levels of antibodies, which, through the mediation of lymphocyte T cells, elicits the suppression of the Th-1 response and T-cell cytotoxic proliferation in overexpressed tumor-antigens [174]. Here, ERBB2 is linked to neoplasm.